Cargando…
The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries
BACKGROUND: Most previous studies concerning the validity of the EQ-5D-3L items refer to applications of only a single language version of the EQ-5D-3L in only one country. Therefore, there is little information concerning the extent to which the results can be generalised across different language...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263046/ https://www.ncbi.nlm.nih.gov/pubmed/25479769 http://dx.doi.org/10.1186/s12955-014-0181-5 |
_version_ | 1782348497154998272 |
---|---|
author | Konerding, Uwe Elkhuizen, Sylvia G Faubel, Raquel Forte, Paul Malmström, Tomi Pavi, Elpida Janssen, MF Bas |
author_facet | Konerding, Uwe Elkhuizen, Sylvia G Faubel, Raquel Forte, Paul Malmström, Tomi Pavi, Elpida Janssen, MF Bas |
author_sort | Konerding, Uwe |
collection | PubMed |
description | BACKGROUND: Most previous studies concerning the validity of the EQ-5D-3L items refer to applications of only a single language version of the EQ-5D-3L in only one country. Therefore, there is little information concerning the extent to which the results can be generalised across different language versions and/or different countries. Here the validity of the EQ-5D-3L items is investigated for six different language versions in six different countries. METHODS: Data came from 1341 type 2 diabetes patients (England: 289; Finland: 177; Germany: 255; Greece: 165; the Netherlands: 354; Spain: 101). The relationships of the five EQ-5D-3L items with seven different test variables (age, gender, education, previous stroke, problems with heart, problems with lower extremities, problems with eyes), were analysed for each combination of item and test variable. For each combination two logistic regression models with the dichotomised EQ-5D-3L item as dependent variable were computed. The first model contained the test variable and dummy coded countries as independent variables, the second model additionally the terms for the interaction between country and test variable. Statistically significant better fit of the second model was taken as evidence for country specific differences regarding the relationship. When such differences could be attributed mainly to one country the analyses were repeated without the data from this country. Validity was investigated with the remaining data using results of the first models. RESULTS: Due to lack of variation in the Spanish data only 31 of the originally intended 35 interaction tests could be performed. Only three of these yielded a significant result. In all three cases the Spanish data deviated most. Without the Spanish data only 1 of the 35 interaction tests yielded a significant result. With 3 exceptions, the tendency of reporting problems increased with age, female gender, lower education, previous stroke, heart problems, problems with lower extremities and problems with eyes for all EQ-5D-3L items. CONCLUSION: The results concerning the European Spanish version are ambiguous. However, the items of the English, Finnish, German, Greek and Dutch versions of the EQ-5D-3L relate in substantially the same way to the test variables. Mostly, these relationships indicate the items’ validity. |
format | Online Article Text |
id | pubmed-4263046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42630462014-12-12 The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries Konerding, Uwe Elkhuizen, Sylvia G Faubel, Raquel Forte, Paul Malmström, Tomi Pavi, Elpida Janssen, MF Bas Health Qual Life Outcomes Research BACKGROUND: Most previous studies concerning the validity of the EQ-5D-3L items refer to applications of only a single language version of the EQ-5D-3L in only one country. Therefore, there is little information concerning the extent to which the results can be generalised across different language versions and/or different countries. Here the validity of the EQ-5D-3L items is investigated for six different language versions in six different countries. METHODS: Data came from 1341 type 2 diabetes patients (England: 289; Finland: 177; Germany: 255; Greece: 165; the Netherlands: 354; Spain: 101). The relationships of the five EQ-5D-3L items with seven different test variables (age, gender, education, previous stroke, problems with heart, problems with lower extremities, problems with eyes), were analysed for each combination of item and test variable. For each combination two logistic regression models with the dichotomised EQ-5D-3L item as dependent variable were computed. The first model contained the test variable and dummy coded countries as independent variables, the second model additionally the terms for the interaction between country and test variable. Statistically significant better fit of the second model was taken as evidence for country specific differences regarding the relationship. When such differences could be attributed mainly to one country the analyses were repeated without the data from this country. Validity was investigated with the remaining data using results of the first models. RESULTS: Due to lack of variation in the Spanish data only 31 of the originally intended 35 interaction tests could be performed. Only three of these yielded a significant result. In all three cases the Spanish data deviated most. Without the Spanish data only 1 of the 35 interaction tests yielded a significant result. With 3 exceptions, the tendency of reporting problems increased with age, female gender, lower education, previous stroke, heart problems, problems with lower extremities and problems with eyes for all EQ-5D-3L items. CONCLUSION: The results concerning the European Spanish version are ambiguous. However, the items of the English, Finnish, German, Greek and Dutch versions of the EQ-5D-3L relate in substantially the same way to the test variables. Mostly, these relationships indicate the items’ validity. BioMed Central 2014-12-05 /pmc/articles/PMC4263046/ /pubmed/25479769 http://dx.doi.org/10.1186/s12955-014-0181-5 Text en © Konerding et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Konerding, Uwe Elkhuizen, Sylvia G Faubel, Raquel Forte, Paul Malmström, Tomi Pavi, Elpida Janssen, MF Bas The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title | The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title_full | The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title_fullStr | The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title_full_unstemmed | The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title_short | The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries |
title_sort | validity of the eq-5d-3l items: an investigation with type 2 diabetes patients from six european countries |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263046/ https://www.ncbi.nlm.nih.gov/pubmed/25479769 http://dx.doi.org/10.1186/s12955-014-0181-5 |
work_keys_str_mv | AT konerdinguwe thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT elkhuizensylviag thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT faubelraquel thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT fortepaul thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT malmstromtomi thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT pavielpida thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT janssenmfbas thevalidityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT konerdinguwe validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT elkhuizensylviag validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT faubelraquel validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT fortepaul validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT malmstromtomi validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT pavielpida validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries AT janssenmfbas validityoftheeq5d3litemsaninvestigationwithtype2diabetespatientsfromsixeuropeancountries |